TRAVERE THERAPEUTICS INC. - COMMON STOCK

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

14 7月 2021 16:30:00 条件 Nasdaq GlobeNewswire

Travere Therapeutics Announces Presentation of Abstracts at ERA-EDTA Congress 2021

04 6月 2021 08:00:00 条件 Nasdaq GlobeNewswire

Travere Therapeutics Completes Enrollment in Pivotal Phase 3 PROTECT Study of Sparsentan in IgA Nephropathy

02 6月 2021 08:00:01 条件 Nasdaq GlobeNewswire

Travere Therapeutics to Present at Upcoming Investor Conferences

27 5月 2021 16:30:00 条件 Nasdaq GlobeNewswire

Travere Therapeutics Provides Regulatory Update on Sparsentan Development Program for Focal Segmental Glomerulosclerosis

25 5月 2021 16:01:00 条件 Nasdaq GlobeNewswire

Travere Therapeutics Reports First Quarter 2021 Financial Results

06 5月 2021 16:01:02 条件 Nasdaq GlobeNewswire

Travere Therapeutics to Present at the BofA Securities 2021 Virtual Health Care Conference

27 4月 2021 16:30:00 条件 Nasdaq GlobeNewswire

Travere Therapeutics to Report First Quarter 2021 Financial Results

26 4月 2021 16:30:00 条件 Nasdaq GlobeNewswire

Travere Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results

01 3月 2021 16:01:01 条件 Nasdaq GlobeNewswire

Travere Therapeutics Recognizes Rare Disease Day 2021 and the Importance of Working Together to Innovate and Address Healthcare Disparities in Rare Disease

25 2月 2021 08:00:02 条件 Nasdaq GlobeNewswire